In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera (scientific article published on 16 February 2007)

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

Q28368930

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Q29616607

Epidemiology of invasive candidiasis: a persistent public health problem

Q29616758

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Q30452376

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

Q33935389

Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], [...]

Q33974186

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

Q34228214

Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis

Q35127833

The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy

Q35185757

Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients

Q35819117

Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature

Q36327963

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

Q37118666

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

Q37157546

In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Q39077602

Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus

Q39475635

Characterization of an azole-resistant Candida glabrata isolate

Q40088759

Compounds active against cell walls of medically important fungi

Q40889532

The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer

Q43923734

Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods

Q44019731

Comparison of caspofungin and amphotericin B for invasive candidiasis

Q44255071

Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method

Q44257296

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

Q44417870

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Q44564495

Initial results from a longitudinal international surveillance programme for anidulafungin (2003).

Q45162980

Candida glabrata fungemia: experience in a tertiary care center

Q46687280

Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient

Q46971624

Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host

Q71554796

Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice

Q71822577

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

Q78144262

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

Candida glabrata

Q139137

P304

page(s)

1616-1620

P577

publication date

2007-02-16

P1433

published in

Antimicrobial Agents and Chemotherapy

Q578004

P1476

title

In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera

P478

volume

Reverse relations

cites work (P2860)

Q37653647	A clinical review of echinocandins in pediatric patients
Q43153532	Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels
Q44563761	Anidulafungin: experimental therapy of fungal infections in animal models
Q28388030	Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong
Q92921364	Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal
Q41990022	Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.
Q39701953	Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections
Q35806170	Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata
Q41787736	Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints
Q37554055	Current perspectives on echinocandin class drugs
Q43276349	Delivery of antifungal agents using bioactive and nonbioactive bone cements
Q36933000	Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
Q36376559	Dose escalation studies with caspofungin against Candida glabrata
Q37822777	Echinocandin antifungal drugs in fungal infections: a comparison
Q37718385	Echinocandin pharmacodynamics: review and clinical implications.
Q38027469	Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
Q38254290	Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management
Q42706331	Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots.
Q39458862	Echinocandins in antifungal pharmacotherapy.
Q38633102	Echinocandins: The Expanding Antifungal Armamentarium
Q37974743	Echinocandins: are they all the same?
Q42545839	Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint
Q41361550	Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi
Q42035300	Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin
Q37855152	In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
Q36425025	In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
Q36932989	In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model
Q42119802	Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin
Q51027528	Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
Q38119554	Invasive fungal infections in newborns and current management strategies
Q38550402	Mechanisms of echinocandin antifungal drug resistance
Q37124868	Micafungin for the prophylaxis and treatment of Candida infections
Q35026516	Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
Q48163141	Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds.
Q35689277	Occidiofungin's chemical stability and in vitro potency against Candida species
Q47410811	Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata
Q37785979	Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections
Q37359613	Pharmacology and antifungal properties of anidulafungin, a new echinocandin
Q37720794	Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
Q42235292	Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans
Q28477349	Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures
Q36828156	The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety
Q36551326	The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata
Q46600214	The role of anidulafungin therapy in solid organ transplant recipients